Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Intellia Therapeutics, Inc. (NTLA : NSDQ)
 
 • Company Description   
Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.?

Number of Employees: 485

 
 • Price / Volume Information   
Yesterday's Closing Price: $45.96 Daily Weekly Monthly
20 Day Moving Average: 1,221,953 shares
Shares Outstanding: 75.85 (millions)
Market Capitalization: $3,486.24 (millions)
Beta: 2.14
52 Week High: $202.73
52 Week Low: $38.85
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.83% -11.06%
12 Week -46.88% -42.36%
Year To Date -61.13% -53.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
40 Erie Street Suite 130
-
Cambridge,MA 02139
USA
ph: 857-285-6200
fax: -
lina.li@intelliatx.com http://www.intelliatx.com
 
 • General Corporate Information   
Officers
John M. Leonard - President; Chief Executive Officer and Director
Glenn Goddard - Executive Vice President; Chief Financial Officer
Fred Cohen - Director
John Crowley - Director
Caroline Dorsa - Director

Peer Information
Intellia Therapeutics, Inc. (CORR.)
Intellia Therapeutics, Inc. (RSPI)
Intellia Therapeutics, Inc. (CGXP)
Intellia Therapeutics, Inc. (BGEN)
Intellia Therapeutics, Inc. (GTBP)
Intellia Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45826J105
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 75.85
Most Recent Split Date: (:1)
Beta: 2.14
Market Capitalization: $3,486.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.30 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 13.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.25
Price/Cash Flow: -
Price / Sales: 92.08
EPS Growth
vs. Year Ago Period: -184.06%
vs. Previous Quarter: -79.82%
Sales Growth
vs. Year Ago Period: 74.58%
vs. Previous Quarter: -12.46%
ROE
03/31/22 - -41.85
12/31/21 - -33.61
09/30/21 - -34.22
ROA
03/31/22 - -33.49
12/31/21 - -26.67
09/30/21 - -26.92
Current Ratio
03/31/22 - -
12/31/21 - 6.11
09/30/21 - 8.35
Quick Ratio
03/31/22 - -
12/31/21 - 6.11
09/30/21 - 8.35
Operating Margin
03/31/22 - -973.48
12/31/21 - -810.49
09/30/21 - -854.10
Net Margin
03/31/22 - -973.48
12/31/21 - -810.49
09/30/21 - -854.10
Pre-Tax Margin
03/31/22 - -
12/31/21 - -810.49
09/30/21 - -854.10
Book Value
03/31/22 - -
12/31/21 - 14.15
09/30/21 - 15.06
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©